Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 1/2018

01-01-2018 | Short Communication

Plasma Cell Dyscrasias in India-2017 Updates

Authors: Arihant Jain, Pankaj Malhotra

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2018

Login to get access

Abstract

Rapid advances are being made in the field of plasma cell dyscrasias. Many abstracts pertaining to the laboratory aspects, clinical features, treatment modalities and outcome of plasma cell dyscrasias were presented at Hematocon 2017. All the total of 24 abstracts pertaining to plasma cell dyscrasias presented at the Hematocon 2017 were reviewed. Out of them 10 were original research and 14 were case reports/short case series. The key findings of original research studies conducted in India are being summarized. Exciting research in the field of plasma cell dyscrasias is being carried out by various centers in the country. Data presented on various aspects of research in plasma cell disorders is encouraging. Multicentric research in the field plasma cell dyscrasias should be encouraged to highlight the various aspects of disease biology and challenges in management unique to our country.
Literature
1.
Naithani R (2017) Hematopoietic stem cell transplantation in India-2017 annual update. Indian J Hematol Blood Transfus. Ahead of print
2.
Kadam Amare PS, Jain H, Nikalje S et al (2016) Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India. Indian J Med Res 144(4):536–543PubMedPubMedCentral
3.
Jain H, Shetty D, Deshpande Y et al (2017) Retrospective fish analysis in 95 multiple myeloma cases and their co-relation with clinico-biochemical parameters. Abstract PCD-05. Indian J Hematol Blood Transfus 33(Abstract Issue: 58th Annual Conference of Indian Society of Hematology and Blood Transfusion; November 2017):S99
4.
5.
Greenberg AJ, Philip S, Paner A et al (2015) Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. Blood Cancer J 5:e271CrossRefPubMedPubMedCentral
6.
7.
Weinhold N, Heuck C, Rosenthal A et al (2016) The clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia 30(2):423–430CrossRefPubMed
8.
Behere PR, Bhattacharyya J, Bithiah GJ (2017) Clinical value of classification of multiple myeloma samples based on their gene expression profiles. Abstract P-PCD04. Indian J Hematol Blood Transfus 33(Abstract Issue: 58th Annual Conference of Indian Society of Hematology and Blood Transfusion):S99
9.
Quinn J, Percy L, Glassford J et al (2010) CD20-positive multiple myeloma—differential expression of cyclins D1 and D2 suggests a heterogeneous disease. Br J Haematol 149(1):156–159CrossRefPubMed
10.
Kapoor P, Greipp PT, Morice WG et al (2008) Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 141(2):135–148CrossRefPubMed
11.
Moreau P, Voillat L, Benboukher L et al (2007) Rituximab in CD20 positive multiple myeloma. Leukemia 21(4):835–836CrossRefPubMed
12.
Padhi S, Varghese RGB, Ramdas A (2013) Cyclin D1 expression in multiple myeloma by immunohistochemistry: case series of 14 patients and literature review. Indian J Med Paediatr Oncol 34(4):283–291CrossRefPubMedPubMedCentral
13.
Athanasiou E, Kaloutsi V, Kotoula V et al (2001) Cyclin D1 overexpression in multiple myeloma a morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens. Am J Clin Pathol 116(4):535–542CrossRefPubMed
14.
Yavasoglu I, Sargin G, Kadikoylu G et al (2015) Immunohistochemical evaluation of CD20 expression in patients with multiple myeloma. Revista Brasileira de Hematologia e Hemoterapia 37(1):34–37CrossRefPubMed
15.
Mallik N, Nampoothiri R, Sreedharanunni S et al (2017) The prognostic impact of CD20 and cyclin D1 expression in multiple myeloma—a pilot study. Abstract P-PCD13. Indian J Hematol Blood Transfus 33(Abstract Issue: 58th Annual Conference of Indian Society of Hematology and Blood Transfusion):S126
16.
Cook JR, Hsi ED, Worley S, Tubbs RR, Hussein M (2006) Immunohistochemical analysis identifies two cyclin D1 + subsets of plasma cell myeloma, each associated with favorable survival. Am J Clin Pathol 125(4):615–624CrossRefPubMed
17.
18.
J-j Zhang, W-j Sun, Z-x Huang et al (2014) Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study. World J Surg Oncol 12(1):234CrossRef
19.
Singh N, Agrawal N, Mehta A et al (2017) Light chain myeloma: a single centre experience. Abstract O06. Indian J of Hematol Blood Transfus 33(Abstract Issue: 58th Annual Conference of Indian Society of Hematology and Blood Transfusion):S4
20.
Ahmed R, Mehta P, Yadav N et al (2017) Initial experience with daratumumab from a tertiary cancer care centre. Abstract P-PCD06. Indian J Hematol Blood Transfus 33(Abstract Issue: 58th Annual Conference of Indian Society of Hematology and Blood Transfusion):S99
Metadata
Title
Plasma Cell Dyscrasias in India-2017 Updates
Authors
Arihant Jain
Pankaj Malhotra
Publication date
01-01-2018
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2018
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-017-0910-0

Other articles of this Issue 1/2018

Indian Journal of Hematology and Blood Transfusion 1/2018 Go to the issue

Original Article

Cost of Treatment of Multiple Myeloma in a Public Sector Tertiary Care Hospital of North India

Original Article

A Study of Preoperative Autologous Blood Donation Timing

Correspondence

Diagnostic Dilemmas in Aggressive Large B Cell Neoplasms with Enigmatic Immunohistochemical Profile: How Far Should We Investigate?

Correspondence

Pediatric cardiac intervention in a case of congenital factor VII deficiency: a challenge to overcome

Original Article

Pilot Study on the Performance of a New System for Image Based Analysis of Peripheral Blood Smears on Normal Samples

Images

Extensive Megakaryocytic Emperipolesis in an Adult Male with Immune Thrombocytopenia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits